ArticleMolecular and cellular biochemistry2026
IL-6 enhances oral squamous cell carcinoma progression associated with JAK2/STAT3-dependent regulation of MMP-10.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is a prevalent malignancy characterized by local invasion, lymphatic metastasis, and poor prognosis. This study aimed to investigate the roles of interleukin-6 (IL-6) and matrix metalloproteinase-10 (MMP-10) in OSCC progression through clinical sample analysis, cellular experiments, and a subcutaneous xenograft model. IL-6 and MMP-10 levels were analyzed in 113 paired OSCC tissues and peritumoral clinically normal tissues using qRT-PCR, immunohistochemistry, and Western blot. Their associations with clinicopathological features and overall survival were also evaluated. Functional assays were conducted in SCC-25 and CAL-27 cells to assess the effects of IL-6 on proliferation, migration, and MMP-10 expression. JAK2/STAT3 pathway inhibitors and MMP-10 overexpression or knockdown were used to evaluate pathway involvement and the functional role of MMP-10. ChIP and luciferase assays examined STAT3 binding to the MMP-10 promoter. IL-6 and MMP-10 levels were elevated in OSCC tissues compared with adjacent non-cancerous tissues, with a positive correlation between IL-6 and MMP-10 expression. High expression of IL-6 or MMP-10 was associated with advanced clinicopathological features and shorter overall survival. The JAK2/STAT3 signaling pathway mediated IL-6-induced MMP-10 upregulation, as this effect was attenuated by pathway inhibition. STAT3 directly bound to the MMP-10 promoter and increased its transcriptional activity. MMP-10 knockdown reduced OSCC cell invasion and shifted EMT-related marker expression, whereas MMP-10 overexpression showed the opposite tendency. In vivo experiments demonstrated that IL-6 administration promoted tumor growth in nude mice, while IL-6 neutralization reduced tumor growth. These results support MMP-10 as a transcriptional target of STAT3 and suggest that the IL-6-JAK2/STAT3-MMP-10 axis contributes to OSCC progression.
Indexed as
Identifiers
42496841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.